Posted by Michael Wonder on 28 Nov 2022
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
28 November 2022 - The treatment will be made available immediately through an early access deal with NHS England.
The commercial agreement between NHS England and Bayer is the first for a prostate cancer therapy and enables early access for eligible NHS patients in England for this indication while NICE completes its on-going appraisal.
